Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CDC42BPB_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CDC42BPB_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDC42BPB_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDC42BPB_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDC42BPB_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDC42BPB_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDC42BPB_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
GO:00315328 | Cervix | CC | actin cytoskeleton reorganization | 31/2311 | 107/18723 | 3.34e-06 | 8.99e-05 | 31 |
GO:00310329 | Cervix | CC | actomyosin structure organization | 43/2311 | 196/18723 | 1.11e-04 | 1.40e-03 | 43 |
GO:00181076 | Cervix | CC | peptidyl-threonine phosphorylation | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
GO:00182106 | Cervix | CC | peptidyl-threonine modification | 26/2311 | 125/18723 | 4.98e-03 | 2.97e-02 | 26 |
GO:000716310 | Endometrium | AEH | establishment or maintenance of cell polarity | 54/2100 | 218/18723 | 1.30e-08 | 8.47e-07 | 54 |
GO:00315329 | Endometrium | AEH | actin cytoskeleton reorganization | 32/2100 | 107/18723 | 1.24e-07 | 5.80e-06 | 32 |
GO:003103210 | Endometrium | AEH | actomyosin structure organization | 46/2100 | 196/18723 | 8.00e-07 | 2.91e-05 | 46 |
GO:00181077 | Endometrium | AEH | peptidyl-threonine phosphorylation | 24/2100 | 116/18723 | 2.14e-03 | 1.65e-02 | 24 |
GO:00182107 | Endometrium | AEH | peptidyl-threonine modification | 25/2100 | 125/18723 | 2.84e-03 | 2.04e-02 | 25 |
GO:000716315 | Endometrium | EEC | establishment or maintenance of cell polarity | 56/2168 | 218/18723 | 5.41e-09 | 3.57e-07 | 56 |
GO:003153214 | Endometrium | EEC | actin cytoskeleton reorganization | 33/2168 | 107/18723 | 7.46e-08 | 3.89e-06 | 33 |
GO:003103214 | Endometrium | EEC | actomyosin structure organization | 46/2168 | 196/18723 | 1.94e-06 | 5.80e-05 | 46 |
GO:001821013 | Endometrium | EEC | peptidyl-threonine modification | 28/2168 | 125/18723 | 4.23e-04 | 4.42e-03 | 28 |
GO:001810713 | Endometrium | EEC | peptidyl-threonine phosphorylation | 26/2168 | 116/18723 | 6.60e-04 | 6.37e-03 | 26 |
GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
GO:003153218 | Esophagus | ESCC | actin cytoskeleton reorganization | 72/8552 | 107/18723 | 5.03e-06 | 5.31e-05 | 72 |
GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
GO:001810710 | Esophagus | ESCC | peptidyl-threonine phosphorylation | 66/8552 | 116/18723 | 9.76e-03 | 3.37e-02 | 66 |
GO:001821010 | Esophagus | ESCC | peptidyl-threonine modification | 70/8552 | 125/18723 | 1.29e-02 | 4.25e-02 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDC42BPB | SNV | Missense_Mutation | | c.1282G>A | p.Glu428Lys | p.E428K | Q9Y5S2 | protein_coding | tolerated(0.82) | benign(0.028) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CDC42BPB | SNV | Missense_Mutation | | c.2113G>C | p.Glu705Gln | p.E705Q | Q9Y5S2 | protein_coding | tolerated(0.5) | benign(0.024) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
CDC42BPB | SNV | Missense_Mutation | | c.1466N>G | p.Lys489Arg | p.K489R | Q9Y5S2 | protein_coding | tolerated(0.29) | benign(0) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDC42BPB | SNV | Missense_Mutation | | c.5025A>C | p.Lys1675Asn | p.K1675N | Q9Y5S2 | protein_coding | tolerated(0.1) | possibly_damaging(0.652) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
CDC42BPB | SNV | Missense_Mutation | | c.3606G>C | p.Lys1202Asn | p.K1202N | Q9Y5S2 | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CDC42BPB | insertion | Frame_Shift_Ins | novel | c.3182_3183insAGTAGTCTTTCACCTCATTAGTCCTT | p.Phe1061LeufsTer59 | p.F1061Lfs*59 | Q9Y5S2 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDC42BPB | deletion | Frame_Shift_Del | novel | c.2773delN | p.Met925TrpfsTer4 | p.M925Wfs*4 | Q9Y5S2 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDC42BPB | deletion | Frame_Shift_Del | novel | c.4689delN | p.Glu1564ArgfsTer15 | p.E1564Rfs*15 | Q9Y5S2 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
CDC42BPB | SNV | Missense_Mutation | rs373755648 | c.4664N>A | p.Arg1555Gln | p.R1555Q | Q9Y5S2 | protein_coding | deleterious(0) | benign(0.285) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CDC42BPB | SNV | Missense_Mutation | novel | c.2202N>C | p.Leu734Phe | p.L734F | Q9Y5S2 | protein_coding | tolerated(0.09) | benign(0.14) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |